Decreasing Costs and Clinic Wait Time While Maintaining Safety for Patients Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) for Multiple Myeloma

被引：1
|
作者：
Inyang, Eno [1 ]
Aktas-Samur, Anil [2 ]
Munshi, Nikhil C. [3 ]
Leblebjian, Hour [1 ]
机构：
[1] Dana Farber Canc Inst, Dept Pharm, Boston, MA 02115 USA
[2] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
[3] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-146605
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
666
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Efficacy and safety of lenalidomide and dexamethasone in overtreated multiple myeloma patients.
    Moscetti, Alessandro
    Resci, Federica
    Antolino, Giusy
    Saltarelli, Francesca
    Monarca, Bruno
    Bianchi, Maria Paola
    Naso, Virginia
    De Benedittis, Daniela
    La Verde, Giacinto
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [32] The efficacy and safety of modified bortezomib-lenalidomide-dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma
    Okazuka, Kiyoshi
    Ishida, Tadao
    Nashimoto, Junichiro
    Uto, Yui
    Sato, Kota
    Miyazaki, Kanji
    Ogura, Mizuki
    Yoshiki, Yumiko
    Abe, Yu
    Tsukada, Nobuhiro
    Suzuki, Kenshi
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2020, 104 (02) : 110 - 115
  • [33] Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Efficacy and Safety Analysis of the Safety Run-in Population of Griffin
    Voorhees, Peter M.
    Rodriguez, Cesar
    Reeves, Brandi
    Nathwani, Nitya
    Costa, Luciano J.
    Lutska, Yana
    Bobba, Padma
    Hoehn, Daniela
    Pei, Huiling
    Ukropec, Jon
    Qi, Ming
    Lin, Thomas S.
    Richardson, Paul G.
    BLOOD, 2020, 136
  • [34] Retrospective Comparison of the Efficacy and Safety of Lenalidomide, Bortezomib and Dexamethasone (RVD) 21-Day Schedule Vs. 28-Day Schedule in Patients with Newly Diagnosed Multiple Myeloma
    Varabyeva, Alina
    Hillengass, Jens
    Ji, Wenyan
    Yu, Han
    Butler, McKenna
    Przespolewski, Eugene
    BLOOD, 2021, 138
  • [35] Updated Results of a Phase 2 Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVd-lite) in Transplant-Ineligible Multiple Myeloma
    O'Donnell, Elizabeth K.
    Laubach, Jacob P.
    Yee, Andrew J.
    Redd, Robert
    Huff, Carol Ann
    Basile, Frank
    Wade, Philip M.
    Paba-Prada, Claudia E.
    Ghobrial, Irene M.
    Schlossman, Robert L.
    Burke, Jill N.
    Harrington, Cynthia C.
    Lively, Kathleen J.
    Lyons, Hannah
    Munshi, Nikhil C.
    Anderson, Kenneth C.
    Richardson, Paul G.
    Raje, Noopur S.
    BLOOD, 2019, 134
  • [36] Mathematical Models for Early Detection of Relapse in Multiple Myeloma Patients Treated with Bortezomib/ Lenalidomide/Dexamethasone
    Otani, Yuki
    Bottino, Dean
    Gupta, Neeraj
    Vakilynejad, Majid
    Tanigawara, Yusuke
    BLOOD, 2022, 140 : 4310 - 4311
  • [37] Lenalidomide, Bortezomib, and Dexamethasone (RVD) In Combination with Vorinostat as Front-Line Therapy for Patients with Multiple Myeloma (MM): Initial Results of a Phase 1 Study.
    Kaufman, Jonathan L.
    Shah, Jatin J.
    Laubach, Jacob P.
    Heffner, Leonard
    Francis, Dixil
    Harvey, R. Donald
    Lewis, Colleen
    Tighiouart, Mourad
    Richardson, Paul
    Orlowski, Robert Z.
    Lonial, Sagar
    BLOOD, 2010, 116 (21) : 1251 - 1251
  • [38] Response and survival outcomes of daratumumab, lenalidomide, bortezomib and dexamethasone (D-RVD) induction in transplant-eligible newly diagnosed multiple myeloma (NDMM) patients
    Joseph, Nisha
    Kaufman, Jonathan
    Lonial, Sagar
    Hofmeister, Craig
    Dhodapkar, Madhav
    Gupta, Vikas
    DiCamillo, Sara
    Roberts, Danielle
    Boise, Lawrence
    Nooka, Ajay
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S113 - S113
  • [39] Impact of lenalidomide-bortezomib-dexamethasone (RVd) induction on patients with newly diagnosed multiple myeloma and renal impairment: Results from the Connect MM Registry.
    Ailawadhi, Sikander
    Lee, Hans Chulhee
    Omel, Jim
    Toomey, Kathleen
    Hardin, James W.
    Gasparetto, Cristina
    Jagannath, Sundar
    Rifkin, Robert M.
    Durie, Brian G.
    Narang, Mohit
    Terebelo, Howard R.
    Wagner, Lynne, I
    Dhalla, Mazaher
    He, Mia
    Srinivasan, Shankar
    Joshi, Prashant Ramesh
    Robinson, Suzanne
    Abonour, Rafat
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [40] Safety and Efficacy of Doxorubicin, Cyclophosphamide, Bortezomib, Dexamethasone and Lenalidomide Followed by Bortezomib Consolidation as First-Line Therapy in Patients with Newly Diagnosed Multiple Myeloma
    Kristian T. Andersen
    Maja Hinge
    Agoston Gyula Szabo
    Erik Segel
    Tina Ormstrup
    Paw C. Holdgaard
    Niels Pallisgaard
    Gitte Kerndrup
    Torben Plesner
    Clinical Hematology International, 2020, 2 (1) : 35 - 39
12345